NCT07444853 Improving the Prognosis for Cerebral Hemorrhage A Study of Clinical, Biological, and Imaging Markers
| NCT ID | NCT07444853 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Tours |
| Condition | Intracerebral Hemorrhage (ICH) |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2026-04-09 |
| Primary Completion | 2036-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2026-04-09 with a primary completion date of 2036-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will establish a prospective, multicenter national cohort of patients with spontaneous intracerebral hemorrhage (ICH). A standardized multimodal database integrating clinical, biological, and imaging data will be collected. The study aims to better characterize ICH patient phenotypes, identify diagnostic and prognostic biomarkers, and describe adherence to evidence-based acute management strategies, including the proportion of patients managed according to the care bundle validated in the INTERACT 3 study. The cohort is also intended to provide a structured platform for translational research and the preparation of future stratified interventional clinical trials in spontaneous ICH.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * Emergency admission to a participating center, with spontaneous intracerebral hemorrhage confirmed by the first brain imaging (CT or MRI) performed at the time of initial treatment; * Obtaining non-opposition Exclusion Criteria: * First brain imaging performed outside a center participating in the study (e.g., peripheral center not recruiting); * Intracerebral hemorrhage secondary to another identified condition, including: * vascular malformation (aneurysm, arteriovenous malformation, cavernoma, etc.); * intracranial tumor; * hemorrhagic transformation of a cerebral infarction; * recent head trauma. * Patient under legal protection; * Patient under guardianship or conservatorship.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07444853 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intracerebral Hemorrhage (ICH). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07444853 currently recruiting?
Yes, NCT07444853 is actively recruiting participants. Contact the research team at m.pasi@chu-tours.fr for enrollment information.
Where is the NCT07444853 trial being conducted?
This trial is being conducted at Angers, France, Lille, France, Toulouse, France, Tours, France.
Who is sponsoring the NCT07444853 clinical trial?
NCT07444853 is sponsored by University Hospital, Tours. The trial plans to enroll 10,000 participants.